Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study
Oncology · 2024
DOI: 10.1159/000534747 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Oncology, 2024. Verfasst von Hiroo Imai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan, hiroo.imai.d8@tohoku.ac.jp. Hauptthemen laut MEDLINE: Etoposide, Carboplatin, Cisplatin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Neuroendocrine carcinoma (NEC) is characterized by a poor prognosis and is generally treated with platinum and etoposide combination therapy as first-line chemotherapy. However, it remains uncertain whether carboplatin and etoposide combination therapy (CE) and cisplatin and etoposide combination therapy (PE) have comparable treatment efficacy. In this retrospective analysis, we compared the efficacy and safety of CE and PE in patients with NEC.
Methods
We retrospectively reviewed the patient’s clinical record from 2005 to 2022 at the Department of Medical Oncology, Tohoku University Hospital. Patients who received either CE or PE were included in the study. Statistical analyses were performed using JMP Pro 16.0 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 104 patients were enrolled, with 73 patients assigned to the CE group and 31 patients assigned to the PE group. Statistically, the response rate, progression-free survival time and overall survival time were 42.6%, 5.1 months (95% CI: 3.5–6.3) and 13.6 months (95% CI: 8.9–17.4), respectively, in the CE groups and 44.4%, 5.6 months (95% CI: 3.1–7.0) and 12.5 months (95% CI: 11.2–14.6), respectively, in the PE groups. There was no significant difference in treatment efficacy between the CE and the PE groups. However, the number of patients with elevated creatinine (3.35 mg/dL and 3.88 mg/dL in 2 patients, respectively) was significantly higher in the PE group than in the CE group.
Conclusion
The efficacy of CE and PE in patients with NEC is comparable. However, the incidence of renal dysfunction was found to be significantly higher in the PE group than in the CE group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan, hiroo.imai.d8@tohoku.ac.jp.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan, hiroo.imai.d8@tohoku.ac.jp.
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Zitieren
APA
Imai, H., Saijo, K., Kawamura, Y., Kodera, S., Komine, K., Iwasaki, T., Takenaga, N., Kasahara, Y., Ouchi, K., Shirota, H., Takahashi, M., & Ishioka, C. (2024). Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study. Oncology. https://doi.org/10.1159/000534747
Vancouver
Imai H, Saijo K, Kawamura Y, Kodera S, Komine K, Iwasaki T, et al. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study. Oncology. 2024. doi:10.1159/000534747
BibTeX
@article{Imai2024,
author = {Imai, Hiroo and Saijo, Ken and Kawamura, Yoshifumi and Kodera, Shuto and Komine, Keigo and Iwasaki, Tomoyuki and Takenaga, Noriko and Kasahara, Yuki and Ouchi, Kota and Shirota, Hidekazu and Takahashi, Masanobu and Ishioka, Chikashi},
title = {Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study},
journal = {Oncology},
year = {2024},
doi = {10.1159/000534747}
}
EUVIMED